
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Most individuals can manage the discomfort of GERD with lifestyle changes and OTC medications.
Insights:
over 4 years ago
Pharmacy Clinical Pearl: Geographic Tongueover 4 years ago
Pharmacy Times is Leading the Wayover 4 years ago
26 Years Strongover 4 years ago
Caffeine and Chocolate Consumption May Trigger Migrainesover 4 years ago
Help Patients Manage Cold and Flu Symptomsover 4 years ago
Pharmacy Clinical Pearl: Cold Sores




